News & Media | Lee's Pharmaceutical
20 DEC 2018

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificialintelligence (AI)-driven pharmaceutical company developing precision medicines in areas ofsignificant unmet medical need……





News & Media

Recent News and Release
09/12/2022
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm was interviewed by Mediazone Group during “Most Valuable Companies in Hong Kong 2022 Awards” Ceremony
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the HKMVC 2022 award with the title of “Most Innovative Pharmaceutical Company”, in recognition of its extensive research and development experience and solid infrastructures. Dr. LI Xiaoyi Benjamin, the Founder and Director of Lee’s Pharm was invited to attend the ceremony and receive the award.

Interview session was featured in the ceremony, giving insight into the achievements and latest development of winning companies. According to Dr. Li, Lee’s Pharm has launched various products in this year, such as the in-licensed products, Teglutik® and INOmax®, which help patients suffering from rare disease. To date, the Group has more than 40 products in its pipeline from early- to late-stage development. More products are expected to be launched in 2023, such as an oncology product treating cervical cancer. Lee’s Pharm focuses on China, Hong Kong and Taiwan market, and is expanding its business to Southeast Asia in 2023 by providing innovative pharmaceutical products, especially in the field of rare disease.

Please click on the video below to watch the full interview.
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings...
20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd (“ZKO”) has recently entered into an exclusive licensing agreement with Nevakar Inc. ("Nevakar"), a US-based privately held, late-stage, biopharmaceutical company developing multiple innovative medications in the ophthalmic and hospital injectable areasfor the development and commercialization of NVK-002 in Greater China (The People’s Republic of China (“PRC”), Hong Kong SAR, Macau SAR and Taiwan), South Korea and the Southeast Asian territories1. NVK-002 is a preservative-free, novel topical eye treatment for slowing the progression of myopia in children and is currently in a Phase 3 clinical trial study ("Childhood Atropine for Myopia Progression" or “CHAMP“ study) in the US and Europe.
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd...
08/03/2024
Zhaoke-Hefei was honored with the “Safe Enterprise” title in Hefei for the year 2023
28/02/2024
Lee’s Pharm was proudly awarded the “Caring Company Logo” for four consecutive years
16/01/2024
The Group’s in-house developed product Socazolimab Injection was successfully launched in China
27/12/2023
“STEM Experience Program for Secondary Students —— Kanya Lee Scholarship Recognition Ceremony 2023”
04/12/2023
The Group’s in-licensed product Adasuve® (Loxapine for Inhalation) obtained Drug Registration Certificate
20/11/2023
Dr. LI Xiaoyi Benjamin, Founder of Lee’s Pharm, was invited to participate in the annual “Rare Diseases Symposium 2023”
16/11/2023
Lee’s Pharmaceutical participated in the Sixth China International Import Expo
18/09/2023
Lee’s Pharm participated in BIOHK2023 and won the “Best Pharmaceutical Company of the Year Award”
16/08/2023
Zhaoke-Hefei won recognition as Innovative SME in Anhui Province
11/07/2023
Dr. LI Xiaoyi, Founder of Lee’s Pharm, was interviewed by Guangdong New Focus program
04/07/2023
Lee’s Pharm honored with “Most Popular (ESG) Enterprise Award” in 1st GBA Excellent ESG Enterprise Election
30/06/2023
Lee’s Pharm achieved a Branding Award after featuring in “Top 100 Chinese Chemical Pharmaceutical Companies Ranking”
02/06/2023
Provincial Center for ADR Monitoring visited Zhaoke-Hefei on assessment of pharmacovigilance system
23/05/2023
Lee’s Pharm successfully held The 8th Pulmonary Arterial Hypertension Summit
15/05/2023
Lee’s Pharmaceutical participated in the 86th PharmChina
02/05/2023
In-licensed product Natulan® (Procarbazine Hydrochloride Capsules) was successfully launched in China
21/04/2023
Sodium Phenylbutyrate Granules won the “Guangdong Famous High-tech Products” award
17/04/2023
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm, was interviewed by Southern Metropolis Daily
13/04/2023
Nadroparin Calcium Injection won the bid in China’s new round of drug bulk-buying program
23/03/2023
Zhaoke Lian Fa, a subsidiary of Lee’s Pharm was honoured with “Excellence Enterprise Award of Gold Pilot Award 2022”
03/03/2023
Antiplatelet Thrombolysin developed by Lee’s Pharm was honoured with “Second Prize of the 8th Hefei City Industrial Achievements in Technology and Innovation”
17/02/2023
Lee’s Pharm was proudly awarded the “Caring Company Logo” for three consecutive years
19/01/2023
Inclusion of Treprostinil Injection, Teglutik® and Trittico® in the National Reimbursement Drug List
01/01/2023
“STEM Experience Program for Secondary Students —— Kanya Lee Scholarship Recognition Ceremony 2022”
21/12/2022
“Biotech Kaleidoscope”—— BIOHK 2022 International Convention sponsored by Lee’s Pharm
09/12/2022
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm was interviewed by Mediazone Group during “Most Valuable Companies in Hong Kong 2022 Awards” Ceremony
16/11/2022
Media Interview by Southern Finance Omnimedia Group —— Nansha Plan: Driving R&D and Creating new opportunities for pharmaceutical industry
16/11/2022
Lee’s Pharm participated in “Caring for Rare Disease Community and Achieving Social Harmony” proposal
10/11/2022
Lee’s Pharm was honoured with “Most Valuable Companies in Hong Kong 2022 Awards” by Mediazone Group
09/11/2022
Approval of a drug product AU409 manufactured by Zhaoke Guangzhou to conduct clinical trial in the United States
24/10/2022
Lee’s Pharm has collaborated with Lok Sin Tong Community Pharmacy to donate a total of 900 boxes of masks
17/10/2022
Zhaoke-Hefei was recognized as “2022 Excellent Enterprise of National Intellectual Property” by the China National Intellectual Property Administration
30/09/2022
Azilsartan tablets obtained Drug Marketing Authorization
09/09/2022
Lee’s Pharm sponsored “The Healthcare and Biotech Road Map in Greater Bay Area” Symposium
22/08/2022
New “Excellent” Treatment for Depression ― Lee’s Pharm successfully held Satellite Meeting for Trittico®
25/07/2022
Lee’s Pharm was proudly awarded again the “Caring Company Logo”
18/07/2022
Unicycive announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and certain other Asian markets
16/07/2022
Lee’s flagship product Ferplex® was elected as “2022 Most Valuable Product in Partnership for Drug Store Chain in China”
16/07/2022
Lee’s Pharm was honoured with “2021 Top 100 Chinese Chemical Pharmaceutical Companies” Award
30/06/2022
License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso® and episil® in three cities in China
21/06/2022
New product Teglutik® obtained Drug Registration Certificate
20/05/2022
New product Natulan® obtained Drug Registration Certificate
22/04/2022
New product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization in China
12/04/2022
Signing of the Comprehensive Strategic Cooperation Agreement between Lee’s Pharm and Rongtai Pharmaceutical
05/04/2022
Launching of Lee’s Pharm Flagship Store on Ali’s and Jingdong’s e-commerce platforms in China
13/01/2022
Zhaoke-Hefei was honoured with the award of “2021 Anhui Provincial Role Model Enterprise in Consumer Products Industry”
01/01/2022
Listing on Guidance for Family Choice Pharmacy of Lee’s Pharm signature products — Ferplex® and Yallaferon®
01/01/2022
“STEM Experience Program for Secondary Students — Kanya Lee Scholarship Recognition Ceremony”
29/12/2021
Lee’s Pharm in-house product Yallaferon® was honoured with “2021 Biopharmaceutical Excellent Brand” Award
23/12/2021
Dr. Li Xiaoyi, the founder of Lee’s Pharm was recognized as “High-Level Talent in Guangzhou Nansha New Zone (Free Trade Zone)”
23/12/2021
Lee’s Pharm Mask Donation Campaign, Sending warmth and care to the community
17/09/2021
Zhaoke Oncology was honoured with “2020 Guangzhou High-end, Precision and Sophisticated Firms” Award
03/09/2021
Zhaoke-Hefei was honoured with the award of “Anhui Provincial High-End Brand Cultivation Demonstration Enterprise in Manufacturing Industry”
24/08/2021
Baptist’s Charity Campaign for World Vision International with sponsorship from Lee’s Pharm
23/08/2021
Patented Technology “Purification of Snake Venom from Viperidae” developed by Zhaoke-Hefei was honoured with “The 8th Anhui Provincial Patent Excellence Award”
26/07/2021
Lees Pharm was honoured with 2020 Top 100 ranking of Chinese Chemical Pharmaceutical Companies
24/06/2021
The New Product “Sodium Phenylbutyrate” from Lee’s Pharm — Bringing hope to rare disease patients — Lee’s Pharm participated in the Multidisciplinary Expert Seminar on Urea Cycle Disorders
07/06/2021
Lee’s Pharm attended the Rare Diseases Conference of Guangdong Medical Association
04/06/2021
Lee’s Pharm Sponsored Symposium at the Sexual Medicine Course for Providers of Women’s Health Care
21/10/2020
HKSTP InnoAcademy — Technology Leaders of Tomorrow programme
20/10/2020
Dr Benjamin Li, CEO of Lee’s Pharmaceutical Holdings Limited was interviewed by TVB on 15 October 2020 sharing our unique concept of mask production by Powder Pharmaceuticals Incorporated (Interview Video)
20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
11/10/2020
Concludes Series B Fundraising of approximately US$145 million for Zhaoke Ophthalmology — Marks Big Step Towards Achieving Possible Spin-off and Separate Listing
10/03/2020
HKBIO and Lee’s Pharm Mask Donation Campaign
03/03/2020
Donation of ERT-PCR Technology for New Coronavirus Detection Press Conference
30/10/2019
Lee’s Pharm Cardiovascular Products Meeting of the 30th GW-ICC
29/10/2019
Greater Pediatrics, Greater Kids, Greater China ——Ferplex of Lee’s Pharmaceutical Holdings Ltd. appeared in the 24th Congress of Chinese Pediatric Society
21/10/2019
Pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus)
14/10/2019
Building a Bridge; China-Italy Cooperation in Medical Education
24/09/2019
Wen Guohui, Deputy Secretary of the CPC Guangzhou Municipal Committee and Mayor of Guangzhou visited Zhaoke Pharmaceutical (Guangzhou) Ltd.
09/09/2019
Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China
01/09/2019
East Meets West – Lee’s Pharm 9th Perinatal Medical Forum in Beijing
20/08/2019
INOMAX pre-NDA meeting
02/04/2019
RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in China
20/12/2018
Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia
06/09/2018
SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in ChinaPhase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer